Browse
THAO
MW:
154.167
logP:
-0.136
H-acceptors:
3
H-donors:
2
Rotatable bonds:
0
GATs:
 
GAT1:
1000 µM
GAT2:
4500 µM
GAT3:
>3000 µM
GAT4:
>10000 µM
THPO
MW:
140.14
logP:
-0.586
H-acceptors:
3
H-donors:
2
Rotatable bonds:
0
GATs:
501 µM
GAT1:
 
GAT2:
 
GAT3:
 
GAT4:
 
THPO
MW:
140.14
logP:
-0.586
H-acceptors:
3
H-donors:
2
Rotatable bonds:
0
GATs:
262 µM
GAT1:
 
GAT2:
 
GAT3:
 
GAT4:
 
THPO
MW:
140.14
logP:
-0.586
H-acceptors:
3
H-donors:
2
Rotatable bonds:
0
GATs:
 
GAT1:
2000 µM
GAT2:
 
GAT3:
1000 µM
GAT4:
 
THPO
MW:
140.14
logP:
-0.586
H-acceptors:
3
H-donors:
2
Rotatable bonds:
0
GATs:
 
GAT1:
1000 µM
GAT2:
3000 µM
GAT3:
800 µM
GAT4:
5000 µM
cis-ACBD
MW:
159.14
logP:
-1.28
H-acceptors:
4
H-donors:
3
Rotatable bonds:
3
EAATs:
133 µM
EAAT1:
 
EAAT2:
 
EAAT3:
 
EAAT4:
 
EAAT5:
 
Brain region: cerebellum (granule cells)
Method: Radioactive labelling
Substrate: n/a
Comment: The authors claim that cis-ACBD is a competitive substrate rather than a non-transportable inhibitor.
The radioactive ligand was D-3H-aspartate.
t-PDC
MW:
159.14
logP:
-0.985
H-acceptors:
5
H-donors:
3
Rotatable bonds:
2
EAATs:
38 µM
EAAT1:
 
EAAT2:
 
EAAT3:
 
EAAT4:
 
EAAT5:
 
Brain region: cerebellum (granule cells)
Method: Radioactive labelling
Substrate: n/a
Comment: The authors claim that L-trans-2,4-PDC is a competitive substrate rather than a non-transportable inhibitor.
The radioactive ligand was D-3H-aspartate.
DL-threo-3-BnOAsp
MW:
253.21
logP:
-0.2
H-acceptors:
6
H-donors:
2
Rotatable bonds:
3
EAATs:
 
EAAT1:
 
EAAT2:
 
EAAT3:
4.9 µM
EAAT4:
 
EAAT5:
 
2-phenyl-4,5-dihydrooxazole-4,5-dicarboxylic acid
MW:
235.19
logP:
0.91
H-acceptors:
5
H-donors:
3
Rotatable bonds:
3
EAATs:
 
EAAT1:
 
EAAT2:
 
EAAT3:
530 µM
EAAT4:
 
EAAT5:
 
(4s,5s)-2-phenyloxazoline-4,5-dicarboxylic acid
MW:
235.19
logP:
0.91
H-acceptors:
6
H-donors:
2
Rotatable bonds:
3
EAATs:
 
EAAT1:
 
EAAT2:
 
EAAT3:
42 µM
EAAT4:
 
EAAT5: